Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.44 |
| ▸ | PNP | P00491 | 2/20 | 0.43 |
| ▸ | TK1 | P04183 | 1/20 | 0.42 |
| ▸ | GART | P22102 | 2/20 | 0.41 |
| ▸ | ATIC | P31939 | 2/20 | 0.41 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.41 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29286377 | 0.87 | TK1 (0.46) | ALDH1A1HPRT1PNPTK1HPGD | |
| SCHEMBL20472443 | 0.86 | AKR1B1 (0.44) | ALDH1A1SMN1; SMN2HPRT1AKR1B1PNP | |
| SCHEMBL48362 | 0.85 | TK1 (0.51) | ALDH1A1SMN1; SMN2HPRT1PNPTK1 | |
| SCHEMBL27710751 | 0.82 | ADORA2A (0.52) | ALDH1A1TK1 | |
| SCHEMBL48223 | 0.82 | PNP (0.42) | ALDH1A1SMN1; SMN2HPRT1PNPTK1 | |
| SCHEMBL1665132 | 0.81 | TK1 (0.47) | ALDH1A1SMN1; SMN2HPRT1PNPTK1 | |
| SCHEMBL7977785 | 0.81 | TK1 (0.64) | HPRT1PNPTK1 | |
| Beta-Alanine SCHEMBL23300588 | 0.81 | AKR1B1 (0.41) | ALDH1A1SMN1; SMN2HPRT1AKR1B1PNP | |
| SCHEMBL28712711 | 0.80 | PNP (0.42) | ALDH1A1SMN1; SMN2HPRT1PNPTK1 | |
| SCHEMBL7984151 | 0.79 | BLM (0.46) | ALDH1A1SMN1; SMN2HPRT1PNPTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110612119-A | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2019-12-24 | — | — | CN | claimed |
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | claimed |
| CN-110612119-B | Phosphatidylether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2024-10-29 | — | — | CN | disclosed |
| US-20240226160-A9 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240131072-A1 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-04-25 | — | — | US | disclosed |
| EP-4291571-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117177989-A | Activity-inducible fusion proteins with heat shock protein 90 binding domain | 西雅图儿童医院以西雅图儿童研究机构名义经营 | 2023-12-05 | — | — | CN | disclosed |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | SEATTLE CHILDREN’S HOSPITAL DBA SEATTLE CHILDREN’S RES INSTITUTE (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230172981-A1 | METHODS AND COMPOSITIONS FOR STIMULATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS WITH HAPTEN LABELLED CELLS | SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST (US) | 2023-06-08 | — | — | US | disclosed |
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | SEATTLE CHILDREN'S HOSPITAL (US) | 2023-05-16 | — | — | US | disclosed |
| US-11466257-B2 | Cell-derived viral vaccines with low levels of residual cell DNA | Seqirus UK Limited (GB) | 2022-10-11 | — | — | US | disclosed |
| US-20100015670-A1 | METHOD OF MODIFYING NUCLEOTIDE CHAIN | PANASONIC CORPORATION (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20090304729-A1 | CELL-DERIVED VIRAL VACCINES WITH LOW LEVELS OF RESIDUAL CELL DNA | NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO KG (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-1647592-B1 | METHOD OF MODIFYING NUCLEOTIDE CHAIN | PANASONIC CORP (JP) | 2009-03-11 | — | — | EP | disclosed |
| EP-2028272-A1 | METHOD OF MODIFYING NUCLEOTIDE CHAIN | Panasonic Corporation (JP) | 2009-02-25 | — | — | EP | disclosed |
| CN-101365480-A | Cell-derived viral vaccines with reduced levels of residual cellular DNA via beta-propiolactone treatment | NOVARTIS VACCINES & DIAGNOSTIC (DE) | 2009-02-11 | — | — | CN | disclosed |
| EP-1951296-A2 | CELL-DERIVED VIRAL VACCINES WITH LOW LEVELS OF RESIDUAL CELL DNA | Novartis Vaccines and Diagnostics GmbH & Co. KG (DE) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007052163-A2 | CELL-DERIVED VIRAL VACCINES WITH LOW LEVELS OF RESIDUAL CELL DNA BY BETA-PROPIOLACTONE TREATMENT | NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO KG (DE) | 2007-05-10 | — | — | WO | disclosed |
| US-20070077629-A1 | Method for modifying nucleotide chain | PANASONIC CORPORATION (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1647592-A1 | METHOD OF MODIFYING NUCLEOTIDE CHAIN | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2006-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090304729-A1 | CELL-DERIVED VIRAL VACCINES WITH LOW LEVELS OF RESIDUAL CELL DNA | DNMT3L, MGMT, MPG | ALDH1A1 3284/4885SMN1; SMN2 3485/4885HPRT1 2996/4885 |
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | PHOSPHO1, LCAT, CD47 | ALDH1A1 3262/4885SMN1; SMN2 1861/4885HPRT1 2122/4885 |
| US-11466257-B2 | Cell-derived viral vaccines with low levels of residual cell DNA | DNMT3L, MGMT, MPG | ALDH1A1 3284/4885SMN1; SMN2 3485/4885HPRT1 2996/4885 |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | PHOSPHO1, LCAT, CD47 | ALDH1A1 3262/4885SMN1; SMN2 1861/4885HPRT1 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.